# Schall, Brown & Schwartz Investigates Krystal Biotech After Q3 Data Delay Sends Shares Down Nearly 11%

> Schall, Brown & Schwartz is investigating Krystal Biotech over statements tied to its November 2, 2026 Q3 results.

- Published: 2026-11-19T05:54:49+00:00
- Section: Legal & Disputes
- Author: News Desk
- URL: https://newsforagent.com/news/2026-11-19/krystal-biotech-sbs-securities-investigation
- Source: [Business Wire](https://www.businesswire.com/news/home/20261118165930/en/)

## Key takeaways

- Schall, Brown & Schwartz LLP is investigating Krystal Biotech for possible securities law violations.
- Krystal said on November 2, 2026 that data releases for several products would move to 2027 from 2026.
- Krystal's shares fell nearly 11% after the Q3 results and data delay were disclosed.

Schall, Brown & Schwartz LLP is investigating Krystal Biotech, Inc. for possible violations of the securities laws, the firm said in a [Business Wire](https://www.businesswire.com/news/home/20261118165930/en/) announcement. The investigation concerns whether the company made false or misleading statements or withheld information from investors.

## What the SBS Investigation Covers

The firm said its inquiry centers on statements Krystal issued and on information it may have failed to disclose. Krystal reported third-quarter financial results on November 2, 2026, and said data releases tied to several of its products would be delayed to 2027 after previously stating the data would be available in 2026. Shares of Krystal fell by nearly 11% on that news, according to the firm's announcement.

Schall, Brown & Schwartz describes itself as a national shareholder rights litigation firm. The announcement names Brian Schall, Andrew Brown and David Schwartz as founding partners. "The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors," the firm said in the announcement.

[Krystal Biotech](https://akta.pro/company-profiles/00022tg/krystal-biotech) is a commercial-stage biotechnology company in Pittsburgh that develops redosable gene therapies on a proprietary HSV-1 vector platform. Its lead product, VYJUVEK, is approved for dystrophic epidermolysis bullosa, and its pipeline spans respiratory, oncology and ophthalmology indications.

## Krystal's Product and Financial Record

According to akta.pro [company records](https://akta.pro/company-data), the FDA approved VYJUVEK for dystrophic epidermolysis bullosa in May 2023, making it the first FDA-approved topical gene therapy. The UK MHRA granted marketing authorization for VYJUVEK in May 2026, the first genetic medicine approved in the UK for the condition, with up to 12 years of market exclusivity under UK Orphan Designation criteria. The same records show full-year 2025 revenue of $389.1 million, 34% growth over 2024, and full-year 2025 net income of $204.83 million.

## Earlier Krystal Biotech Coverage

On November 17, 2026, Pomerantz LLP said it was investigating Krystal Biotech for potential securities fraud following the November 2 announcement that data releases for several product candidates would be delayed until 2027, GlobeNewswire reported. That report put the stock's decline on the day at 10.95%, to $295.90 per share. On November 11, 2026, Simply Wall St reported that Krystal's third-quarter earnings showed continued profitability and that the company announced a $400 million share repurchase authorization.

## Krystal's November 2 Buyback Authorization

Krystal's board authorized a buyback plan on November 2, 2026, MarketScreener reported, with the plan's terms not disclosed in the announcement. Simply Wall St later reported the authorization at $400 million and said the stock had risen 52% over the past year.

## Companies in this story

- [Krystal Biotech company profile](https://akta.pro/company-profiles/00022tg/krystal-biotech) · website: http://www.krystalbio.com

---
News for Agent · https://newsforagent.com/llms.txt
